Applied Therapeutics (NASDAQ:APLT) Rating Increased to Sell at Wall Street Zen

Wall Street Zen upgraded shares of Applied Therapeutics (NASDAQ:APLT - Free Report) to a sell rating in a research report report published on Thursday.

Separately, Royal Bank of Canada restated a "sector perform" rating and set a $1.50 price objective on shares of Applied Therapeutics in a research note on Wednesday, May 14th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $6.10.

Applied Therapeutics Stock Performance

Shares of NASDAQ:APLT traded up $0.00 during trading hours on Thursday, hitting $0.41. The stock had a trading volume of 834,234 shares, compared to its average volume of 3,190,905. The stock's fifty day simple moving average is $0.42 and its 200 day simple moving average is $1.48. The firm has a market capitalization of $58.05 million, a price-to-earnings ratio of -0.25 and a beta of 2.00. Applied Therapeutics has a 1-year low of $0.30 and a 1-year high of $10.62.

Applied Therapeutics (NASDAQ:APLT - Get Free Report) last posted its earnings results on Monday, April 14th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.06). The company had revenue of $0.00 million during the quarter, compared to analysts' expectations of $0.61 million. As a group, research analysts anticipate that Applied Therapeutics will post -0.65 EPS for the current year.

Institutional Trading of Applied Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of APLT. Vestal Point Capital LP raised its position in Applied Therapeutics by 904.4% in the fourth quarter. Vestal Point Capital LP now owns 11,500,000 shares of the company's stock worth $9,846,000 after acquiring an additional 10,355,000 shares in the last quarter. Propel Bio Management LLC grew its stake in shares of Applied Therapeutics by 17.4% in the 1st quarter. Propel Bio Management LLC now owns 11,285,420 shares of the company's stock worth $5,517,000 after purchasing an additional 1,670,000 shares during the last quarter. T. Rowe Price Investment Management Inc. lifted its stake in Applied Therapeutics by 91.5% during the first quarter. T. Rowe Price Investment Management Inc. now owns 10,380,590 shares of the company's stock valued at $5,076,000 after purchasing an additional 4,959,670 shares during the last quarter. VR Adviser LLC lifted its stake in Applied Therapeutics by 1.7% during the fourth quarter. VR Adviser LLC now owns 9,990,591 shares of the company's stock valued at $8,554,000 after purchasing an additional 165,591 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC boosted its holdings in Applied Therapeutics by 2,458.3% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 8,762,291 shares of the company's stock worth $7,502,000 after buying an additional 8,419,781 shares in the last quarter. Institutional investors own 98.31% of the company's stock.

Applied Therapeutics Company Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.